1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2011. http://www.goldcopd.org/uploads/users/files/GOLD_Report_2011_Feb21.pdf . Accessed 8 Apr 2013.
2. Hudd TR, Zaiken K. Management of chronic obstructive pulmonary disease: an emphasis on recently approved medications and products in the pipeline. Formulary. 2011;46(9):374–93.
3. Atsou K, Chouaid C, Hejblum G. Variability of the chronic obstructive pulmonary disease key epidemiological data in Europe: systematic review. BMC Med. 2011;9:7.
4. World Health Organization. World health statistics. 2008. http://www.who.int/whosis/whostat/EN_WHS08_Full.pdf . Accessed 8 Apr 2013.
5. Novartis Europharm Ltd. Seebri® Breezhaler® (glycopyrronium bromide) powder for inhalation: EU summary of product characteristics. 2012. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002430/WC500133769.pdf . Accessed 8 Apr 2013.